Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists

被引：24
|
作者：
Bui, Kim Tam [1 ]
Cooper, Wendy A. [2 ,3 ,4 ]
Kao, Steven [1 ,4 ]
Boyer, Michael [1 ,4 ]
机构：
[1] Chris OBrien Lifehouse, 119-143 Missenden Rd Camperdown, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[3] Western Sydney Univ, Sch Med, Sydney, NSW 2560, Australia
[4] Royal Prince Alfred Hosp, 50 Missenden Rd Camperdown, Camperdown, NSW 2050, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 08期
关键词：
personalized therapy; non-small cell; lung cancer; targeted therapy; mutation; rearrangement; RANDOMIZED PHASE-III; PLATINUM-BASED CHEMOTHERAPY; OPEN-LABEL; 1ST-LINE TREATMENT; DOUBLE-BLIND; MAINTENANCE THERAPY; EGFR MUTATIONS; SINGLE-ARM; CARBOPLATIN-PACLITAXEL; ACQUIRED-RESISTANCE;
D O I：
10.3390/jcm7080192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC.
引用
收藏
页数：18
相关论文
共 50 条
  • [41] New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer
    Genova, Carlo
    Rijavec, Erika
    Biello, Federica
    Rossi, Giovanni
    Barletta, Giulia
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Coco, Simona
    Alama, Angela
    Grossi, Francesco
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (01) : 19 - 33
  • [42] Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
    Tian, Xueli
    Gu, Tingxuan
    Lee, Mee-Hyun
    Dong, Zigang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (01):
  • [43] Emerging therapies for non-small cell lung cancer
    Zhang, Chao
    Leighl, Natasha B.
    Wu, Yi-Long
    Zhong, Wen-Zhao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [44] Maintenance therapy in non-small cell lung cancer
    Genestreti, Giovenzio
    Di Battista, Monica
    Cavallo, Giovanna
    Bartolotti, Marco
    Brandes, Alba A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (07) : 839 - 846
  • [45] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [46] Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments
    Planchard, D.
    Leprieur, E. Giroux
    REVUE DE PNEUMOLOGIE CLINIQUE, 2011, 67 : S36 - S40
  • [47] Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
    Mustachio, Lisa Maria
    Roszik, Jason
    PHARMACEUTICALS, 2020, 13 (11) : 1 - 14
  • [48] Targeted therapies for non-small cell lung cancer
    Papaetis, G. S.
    Roussos, C.
    Syrigos, K. N.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (27) : 2810 - 2831
  • [49] Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
    Imyanitov, Evgeny N.
    Iyevleva, Aglaya G.
    Levchenko, Evgeny V.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [50] Targeted therapy in non-small cell lung cancer
    Giaccone, G
    LUNG CANCER, 2002, 38 : S29 - S32
12345